KLRAKailera Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Kailera Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KLRAThis | $1.6B#7 | — | 1.5x#3 | — | — | — | — | 0.0%#3 | — | — | — | — |
| PRGO | $1.9B#1 | — | 0.7x#1 | 0.4x#1 | -2.8%#10 | -729.7%#12 | -26.4%#6 | -56.7%#12 | -20.9%#4 | 4#2 | -30.5%#13 | 8.5%#1 |
| ZYME | $1.9B#2 | — | 23.1x#11 | 17.6x#7 | 38.9%#7 | 33.9%#6 | -87.3%#7 | -100.9%#13 | — | — | 65.5%#7 | — |
| BHVN | $1.8B#3 | — | 148.4x#15 | — | — | 12.7%#8 | — | -6045.0%#16 | — | — | -18.4%#11 | — |
| STOK | $1.8B#4 | — | 5.2x#10 | 9.8x#5 | 404.5%#3 | 92.3%#3 | -11.2%#5 | -2.0%#6 | — | — | 20.6%#8 | — |
| SEPN | $1.8B#5 | — | 4.6x#9 | 39.0x#9 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#8 | — | — | 165.5%#4 | — |
| XNCR | $1.8B#6 | — | 3.5x#7 | 14.0x#6 | 13.7%#9 | 60.5%#5 | -141.4%#8 | -18.3%#9 | -31.5%#5 | — | 155.2%#5 | — |
| ANIP | — | 16.1x#3 | — | — | 43.8%#6 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#1 | — | -24.5%#12 | — |
| KARD | $1.6B#8 | — | 2.6x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ETON | $1.6B#9 | — | 34.6x#12 | 20.1x#8 | 104.9%#5 | -20.4%#10 | -1.1%#4 | -9.9%#7 | -1.8%#3 | 4#2 | 220.3%#2 | — |
| ANAB | $1.6B#10 | — | 124.0x#14 | 6.7x#3 | 157.0%#4 | 90.9%#4 | 20.4%#2 | -103.8%#14 | — | — | 180.0%#3 | — |
| SNDX | $1.5B#11 | — | 102.1x#13 | 8.9x#4 | 627.8%#2 | 10.5%#9 | -158.4%#10 | -1890.2%#15 | -1205.8%#6 | — | 14.9%#9 | — |
| AVLN | $1.5B#12 | — | 3.9x#8 | — | — | — | — | 0.0%#3 | — | — | — | — |
| INVA | $1.5B#13 | 4.9x#2 | 1.2x#2 | 3.7x#2 | 14.7%#8 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#1 | 9.8%#10 | — |
| DMRA | $1.5B#14 | 3.2x#1 | 2.9x#5 | — | — | -878.8%#13 | — | -40.7%#11 | — | — | 751.8%#1 | — |
| BCAX | $1.5B#15 | — | 3.1x#6 | — | — | -102.9%#11 | — | -29.4%#10 | — | — | 95.6%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice